Rx Response Planning Tweaks After Successful Efforts In Super Storm Sandy
This article was originally published in The Pink Sheet Daily
HHS and other stakeholders largely praise the work of industry’s Rx Response as a single point of contact for the government and pharmaceutical industry to address pharmaceutical supply chain challenges during Super Storm Sandy.
You may also be interested in...
As meningitis outbreak widens, FDA and members of Congress are calling for clarification of what jurisdiction the agency has over pharmacies, but agency officials are stopping short of asking for clear new authorities.
Pink Sheet Podcast: COVID-19 Stresses Manufacturing, Vaccine Placebo Controls, Thorny FDA Precedents
Pink Sheet reporters and editor discuss the pandemic’s effects on non-coronavirus-related product manufacturing, US FDA efforts to ensure vaccine sponsors maintain placebo controls once a product is available, and precedents that burden the agency.
As CEO Erck touts that its COVID vaccine has the 'best data,' Novavax prepares to enter Phase III trials and inks deal with Serum Institute to boost production even as its 'almost a perfect flu vaccine' remains on hold.